[1]
|
Pharmacogenetics of CYP2C19*17: Functional and Clinical Implications of CYP2C19*17 - rs12248560 (c.-806C>T) in the Development of Type 2 Diabetes
Biomedical and Pharmacology Journal,
2022
DOI:10.13005/bpj/2528
|
|
|
[2]
|
Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study
Current Drug Metabolism,
2020
DOI:10.2174/1389200221999201027200931
|
|
|
[3]
|
Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner
The FASEB Journal,
2020
DOI:10.1096/fj.202000830R
|
|
|
[4]
|
Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo
Medicina Clínica,
2017
DOI:10.1016/j.medcli.2017.02.035
|
|
|
[5]
|
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome
Medicina Clínica (English Edition),
2017
DOI:10.1016/j.medcle.2017.02.030
|
|
|
[6]
|
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
The Pharmacogenomics Journal,
2016
DOI:10.1038/tpj.2015.45
|
|
|
[7]
|
Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype
Journal of Genetics,
2015
DOI:10.1007/s12041-015-0477-1
|
|
|
[8]
|
Impact of clopidogrel treatment on platelet function and thrombogenecity in diabetic patients undergoing elective coronary stenting
Journal of Diabetes Mellitus,
2012
DOI:10.4236/jdm.2012.22025
|
|
|
[9]
|
Distribution ofCYP2D6andCYP2C19Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico
Genetic Testing and Molecular Biomarkers,
2012
DOI:10.1089/gtmb.2012.0055
|
|
|